vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and SANFILIPPO JOHN B & SON INC (JBSS). Click either name above to swap in a different company.
SANFILIPPO JOHN B & SON INC is the larger business by last-quarter revenue ($314.8M vs $185.2M, roughly 1.7× AMICUS THERAPEUTICS, INC.). SANFILIPPO JOHN B & SON INC runs the higher net margin — 5.7% vs 0.9%, a 4.8% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 4.6%). SANFILIPPO JOHN B & SON INC produced more free cash flow last quarter ($40.0M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 7.6%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
John B. Sanfilippo & Son Inc. (JBSS) is a leading US processor, marketer and distributor of high-quality tree nuts, peanuts, dried fruits, and value-added snack products. It serves retail, foodservice, and industrial ingredient customers primarily across North America, offering both branded and private label product lines.
FOLD vs JBSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $314.8M |
| Net Profit | $1.7M | $18.0M |
| Gross Margin | 85.7% | 18.8% |
| Operating Margin | 8.6% | 8.3% |
| Net Margin | 0.9% | 5.7% |
| Revenue YoY | 23.7% | 4.6% |
| Net Profit YoY | -88.5% | 32.1% |
| EPS (diluted) | $0.00 | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $314.8M | ||
| Q3 25 | $169.1M | $298.7M | ||
| Q2 25 | $154.7M | $269.1M | ||
| Q1 25 | $125.2M | $260.9M | ||
| Q4 24 | $149.7M | $301.1M | ||
| Q3 24 | $141.5M | $276.2M | ||
| Q2 24 | $126.7M | $269.6M | ||
| Q1 24 | $110.4M | $271.9M |
| Q4 25 | $1.7M | $18.0M | ||
| Q3 25 | $17.3M | $18.7M | ||
| Q2 25 | $-24.4M | $13.5M | ||
| Q1 25 | $-21.7M | $20.2M | ||
| Q4 24 | $14.7M | $13.6M | ||
| Q3 24 | $-6.7M | $11.7M | ||
| Q2 24 | $-15.7M | $10.0M | ||
| Q1 24 | $-48.4M | $13.5M |
| Q4 25 | 85.7% | 18.8% | ||
| Q3 25 | 88.5% | 18.1% | ||
| Q2 25 | 90.2% | 18.1% | ||
| Q1 25 | 90.7% | 21.4% | ||
| Q4 24 | 90.1% | 17.4% | ||
| Q3 24 | 90.6% | 16.9% | ||
| Q2 24 | 91.1% | 18.5% | ||
| Q1 24 | 87.7% | 18.1% |
| Q4 25 | 8.6% | 8.3% | ||
| Q3 25 | 20.3% | 9.0% | ||
| Q2 25 | -6.1% | 7.5% | ||
| Q1 25 | -6.3% | 10.8% | ||
| Q4 24 | 10.7% | 6.4% | ||
| Q3 24 | 15.3% | 6.2% | ||
| Q2 24 | 11.8% | 5.4% | ||
| Q1 24 | -25.1% | 6.7% |
| Q4 25 | 0.9% | 5.7% | ||
| Q3 25 | 10.2% | 6.3% | ||
| Q2 25 | -15.8% | 5.0% | ||
| Q1 25 | -17.3% | 7.7% | ||
| Q4 24 | 9.8% | 4.5% | ||
| Q3 24 | -4.8% | 4.2% | ||
| Q2 24 | -12.4% | 3.7% | ||
| Q1 24 | -43.9% | 5.0% |
| Q4 25 | $0.00 | $1.53 | ||
| Q3 25 | $0.06 | $1.59 | ||
| Q2 25 | $-0.08 | $1.15 | ||
| Q1 25 | $-0.07 | $1.72 | ||
| Q4 24 | $0.05 | $1.16 | ||
| Q3 24 | $-0.02 | $1.00 | ||
| Q2 24 | $-0.05 | $0.85 | ||
| Q1 24 | $-0.16 | $1.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $2.4M |
| Total DebtLower is stronger | $392.7M | $28.8M |
| Stockholders' EquityBook value | $274.2M | $370.1M |
| Total Assets | $949.9M | $617.7M |
| Debt / EquityLower = less leverage | 1.43× | 0.08× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $2.4M | ||
| Q3 25 | $263.8M | $714.0K | ||
| Q2 25 | $231.0M | $585.0K | ||
| Q1 25 | $250.6M | $1.3M | ||
| Q4 24 | $249.9M | $336.0K | ||
| Q3 24 | $249.8M | $442.0K | ||
| Q2 24 | $260.1M | $484.0K | ||
| Q1 24 | $239.6M | $377.0K |
| Q4 25 | $392.7M | $28.8M | ||
| Q3 25 | $392.0M | $29.8M | ||
| Q2 25 | $391.3M | $14.6M | ||
| Q1 25 | $390.7M | $5.8M | ||
| Q4 24 | $390.1M | $6.0M | ||
| Q3 24 | $389.5M | $6.2M | ||
| Q2 24 | $388.9M | $6.4M | ||
| Q1 24 | $388.4M | $6.6M |
| Q4 25 | $274.2M | $370.1M | ||
| Q3 25 | $230.4M | $362.8M | ||
| Q2 25 | $204.3M | $360.7M | ||
| Q1 25 | $193.6M | $346.6M | ||
| Q4 24 | $194.0M | $325.6M | ||
| Q3 24 | $178.8M | $310.8M | ||
| Q2 24 | $132.5M | $322.6M | ||
| Q1 24 | $130.7M | $321.8M |
| Q4 25 | $949.9M | $617.7M | ||
| Q3 25 | $868.8M | $598.7M | ||
| Q2 25 | $815.3M | $597.6M | ||
| Q1 25 | $789.8M | $590.0M | ||
| Q4 24 | $785.0M | $545.3M | ||
| Q3 24 | $786.6M | $519.4M | ||
| Q2 24 | $749.5M | $515.6M | ||
| Q1 24 | $721.8M | $491.9M |
| Q4 25 | 1.43× | 0.08× | ||
| Q3 25 | 1.70× | 0.08× | ||
| Q2 25 | 1.92× | 0.04× | ||
| Q1 25 | 2.02× | 0.02× | ||
| Q4 24 | 2.01× | 0.02× | ||
| Q3 24 | 2.18× | 0.02× | ||
| Q2 24 | 2.93× | 0.02× | ||
| Q1 24 | 2.97× | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $62.5M |
| Free Cash FlowOCF − Capex | $16.0M | $40.0M |
| FCF MarginFCF / Revenue | 8.6% | 12.7% |
| Capex IntensityCapex / Revenue | 0.2% | 7.1% |
| Cash ConversionOCF / Net Profit | 9.62× | 3.48× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $32.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $62.5M | ||
| Q3 25 | $35.7M | $32.1M | ||
| Q2 25 | $-26.5M | $36.5M | ||
| Q1 25 | $7.8M | $-25.9M | ||
| Q4 24 | $-3.9M | $11.0M | ||
| Q3 24 | $-23.0M | $8.9M | ||
| Q2 24 | $22.7M | $35.2M | ||
| Q1 24 | $-29.7M | $5.3M |
| Q4 25 | $16.0M | $40.0M | ||
| Q3 25 | $35.3M | $7.3M | ||
| Q2 25 | $-28.9M | $23.0M | ||
| Q1 25 | $7.5M | $-37.6M | ||
| Q4 24 | $-4.2M | $-2.7M | ||
| Q3 24 | $-23.3M | $-3.0M | ||
| Q2 24 | $21.6M | $24.4M | ||
| Q1 24 | $-31.5M | $-1.3M |
| Q4 25 | 8.6% | 12.7% | ||
| Q3 25 | 20.9% | 2.4% | ||
| Q2 25 | -18.7% | 8.6% | ||
| Q1 25 | 6.0% | -14.4% | ||
| Q4 24 | -2.8% | -0.9% | ||
| Q3 24 | -16.5% | -1.1% | ||
| Q2 24 | 17.0% | 9.0% | ||
| Q1 24 | -28.5% | -0.5% |
| Q4 25 | 0.2% | 7.1% | ||
| Q3 25 | 0.2% | 8.3% | ||
| Q2 25 | 1.6% | 5.0% | ||
| Q1 25 | 0.2% | 4.5% | ||
| Q4 24 | 0.2% | 4.5% | ||
| Q3 24 | 0.3% | 4.3% | ||
| Q2 24 | 0.9% | 4.0% | ||
| Q1 24 | 1.6% | 2.4% |
| Q4 25 | 9.62× | 3.48× | ||
| Q3 25 | 2.06× | 1.72× | ||
| Q2 25 | — | 2.70× | ||
| Q1 25 | — | -1.29× | ||
| Q4 24 | -0.27× | 0.81× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 3.52× | ||
| Q1 24 | — | 0.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
JBSS
| Sales Channel Directly To Consumer | $263.2M | 84% |
| Sales Channel Commercial Ingredients | $28.0M | 9% |
| Sales Channel Contract Packaging | $23.6M | 8% |
